Sir, I read with interest the recent article by Yeh and Cheng (1997) concerning toxicity of the 5-fluorouracil/leucovorin (HDFL) treatment protocol. The clinical presentation of side-effects was encephalopathy associated with laboratory findings of hyperammonaemia, lactic acidosis and hypotriglyceridaemia. This phenomenon was present in 5.7% of patients treated with the HDFL protocol. The authors conclude that ammonia as the endproduct of 5FU metabolism overloads capacity of the Krebs cycle and that under HDFL treatment a large amount of fluoroacetic acid directly inhibits the ATP-producing Krebs cycle (Yeh and Cheng, 1997) . I have the following comments to make: one should distinguish between the Krebs-Henseleit cycle, which is ureasynthetic, and the Krebs tricarboxylic acid cycle, which generates redox equivalents for the electron transport chain and consequent synthesis of ATP. Both these cellular processes require intact mitochondria to operate. In hepatic encephalopathy it is of interest to assess the clinical stage of encephalopathy using available scoring scales (i.e. Glasgow Coma Scale). The profile of plasma amino acids informs about the elevation of glutamine as this amino acid is an essential part of the ammonia disposal system and is also related to acid-base balance (Guder et al, 1987) . Moreover, other constituents of the ureagenic cycle are also evaluated. Alanine and pyruvate measurements are of value for assessment of the redox status and optimally, AKBR is suggested as the best prognostic and functional test of cytoplasmic (lactate/pyruvate) and mitochondrial (beta-hydroxybutyrate/acetacetate) redox state (Asonuma, 1991; Saibara, 1994; Takahashi, 1997) . Hypotriglyceridaemia is usually accompanied by elevated serum free fatty acids and hypoglycaemia usually develops because of liver gluconeogenesis failure. Altogether, these findings indicate severe disturbance of the liver function in terms of (a) impaired ureagenesis (elevated ammonia, elevated glutamine, decreased urea, alkalosis); (b) impaired oxidative phosphorylation (lactate/pyruvate); and (c) impaired synthesis of complex lipoproteins. Interpretation of these findings is, in my opinion, consistent with hepatic dysfunction; the authors assumed that none of their patients had hepatic or renal dysfunction.
The frequency of this complication, which was 5.7% in the group under study, is high and could imply a certain genetic basis. I wish to offer the following differential diagnostic considerations to complement those discussed by Yeh and Cheng. Dihydropyrimidine dehydrogenase deficiency in its incomplete form remains a possibility (Wei et al, 1996) as the complexity of the compound-heterozygous status in which both alleles harbour different functionally more or less relevant mutations (also called polymorphisms) may trigger a complex clinical response under stress conditions (i.e. substrate loading superimposed on disease status). Mitochondrial disorders are another possibility (OMIM 1996) . Their genetics are based on the populational rather than on a Mendelian basis and their spectrum of clinical presentation is extremely broad. Loss of structural integrity of mitochondria leads to disruption of the proton gradient and consequently to failure of energy (ATP) production. In the liver, these events result in failure of the Krebs-Henseleit ureasynthetic cycle and consequent hyperammonaemia. Lactic acidosis develops because of derangement (regardless of the nature) of the cellular redox status and microvesicular fatty infiltration (in the liver) appears because of inability to create and export complex lipoproteins. Again, one can hypothesize that a stress situation superimposed on a genetically altered background (i.e. certain proportion of primarily malfunctioning mitochondria) may trigger a response such as this. Liver toxicity of several pyrimidine derivatives has been previously demonstrated for AZT (Mondica-Napolitano, 1993) and fialuridine (Lewis et al, 1996) and the mechanism was related to damaged mitochondria. The inability of mitochondria to synthesize thymidine de novo may be the single most important reason for mitochondrial toxicity of pyrimidine analogues (Shaw and Locarnini 1995). The point raised by Yeh and and Cheng is important for two reasons: (a) assessment of patients with this pathological reaction to HDFL treatment should be comprehensive and in addition should include determinations of plasma amino acids and pyruvate; (b) when these side-effects occur the clinician in charge should consider consultation with a medical geneticist to review possibilities mentioned above in the context of the patient's family history. Gaining experience and knowledge could perhaps result in delineation of a test protocol assessing the pharmacogenetic background of patients scheduled for HDFL treatment. Notably, the importance of pharmacogenetics in cancer treatment has already been recognized for thiopurine methyltransferases (Szumlanski et al 1996) and dihydropynimidine dehydrogenases (Meinsma et al, 1995; Beuzeboc, et al, 1996 We greatly appreciate Dr Valik's comments, which have provided new information for studying the possible pathogenetic mechanisms of HDFL-related encephalopathy. However, we would like to take this opportunity to clarify some of the points that we raised in the original article (Yeh et al, 1997) . The two Krebs cycles mentioned by Dr Valik, i.e. the Krebs tricarboxylic acid cycle (Krebs citric acid cycle) and the Krebs-Henseleit urea cycle, correspond to the Krebs cycle and the urea cycle in our article respectively. We considered that these two simplified terms are well accepted by readers and are widely used in the literature (Lehninger et al, 1993a,b; Mayes et al, 1993; Rodwell et al, 1993) . We believed that the metabolic encephalopathy observed by us was a new pathogenetic entity, which differed significantly from the more common hepatic encephalopathy. Therefore, we chose not to use the traditional clinical grading system for hepatic encephalopathy (Sherlock et al, 1954 (Sherlock et al, , 1989 . We have indeed documented that none of our patients had hepatic or renal dysfunction in terms of the conventional biochemical criteria (Yeh et al, 1997) . Also, none of them had hypoglycaemia.
The relatively high overall incidence (5.7%) of HDFL-related encephalopathy in our patients did not necessarily imply a genetic basis for this condition. Instead, all our evidence has indicated that dihydropyrimidine dehydrogenase (DPD) deficiency, even in its incomplete form, is probably not the pathogenetic mechanism of HDFL-related encephalopathy. 5-FU treatment in patients with DPD deficiency should result in severe mucosal and haematological toxicities (Tuchman et al, 1985; Diasio et al, 1988) , which were definitely not observed in all our 16 patients. Also, the encephalopathy due to DPD deficiency should characteristically present at the first exposure to drug, and should have low or no catabolic products (such as ammonia) of 5-FU (Tuchman et al, 1985; Diasio et al, 1988; Takimoto et al, 1996) . Among our 16 patients, the encephalopathy developed at the first exposure to HDFL in eight patients, but developed at or after the second exposure in another eight patients. On rechallenge with HDFL, only 8 out of 12 patients developed recurrent encephalopathy. These observations strongly argued that DPD deficiency is the cause of HDFL-related encephalopathy.
We suggest that there are at least two distinct pathogenetic entities of 5-FU-related encephalopathy. The first is the 'DPD deficiency type'. DPD deficiency results in failure of the first step of 5-FU catabolism and leads to 5-FU accumulation (Tuchman et al, 1985; Diasio et al, 1988; Takimoto et al, 1996) . High concentration of 5-FU penetrates into cerebrospinal fluid (CSF) and causes acute demyelination of the neurons. After discontinuation of 5-FU, it usually takes weeks to months for remyelination to occur (Kerr et al, 1984; Takimoto et al, 1996) . High plasma level of 5-FU should also cause severe gastrointestinal (GI) and marrow toxicities (Tuchman et al, 1985; Diasio et al, 1988; Takimoto et al, 1996) . And few or no catabolites (FUPA, 5-fluoroureidopropionic acid; FBAL, 2-fluoro-fi-alanine; ammonia, etc.) should be detected because of the failure of 5-FU catabolism. The second is the '5-FU catabolite type ' (Yeh et al, 1997) . The major catabolic pathway of 5-FU is intact. However, the relatively large dose of 5-FU results in transient accumulation of 5-FU catabolites (including ammonia). If the disposal of the latter is not adequate, such as under conditions of malnutrition and/or impaired Krebs cycle, transient encephalopathy ensues. No demyelinating changes and no severe GI or marrow toxicities should be observed, and recovery from encephalopathy usually occurs within a few days (Yeh et al, 1997) . Theoretically, a specific DPD inhibitor (such as 5-ethynyluracil) may protect the patients from the encephalopathy of the 5-FU catabolite type (Davis et al, 1994) .
We, however, cannot completely exclude other possible mechanisms of the hyperammonaemia observed in our patients. The one raised by Dr Valik, which hypothesized that a stress situation superimposed on a genetically altered background in urea cycle (i.e. incomplete form of urea cycle enzyme deficiencies, such as ornithine transcarbamoylase deficiency) is certainly a possibility that deserves further exploration (Sinatra et al, 1975; Snodgrass et al, 1976) . We also agree with Dr Valik that patients with HDFLrelated encephalopathy should have an examination of plasma amino acids (glutamine, arginine, etc.) and the intermediates of urea cycle (ornithine, citrulline, argininosuccinate, etc.) (Rodwell
